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ABSTRACT
Seminomas and nonseminomas represent the invasive stages of testic-
ular (TGCTs) of adolescents and adults. Although TGCTs are character-
ized by extra copies of the short arm of chromosome 12, the genetic basis
for gain of 12p in the pathogenesis of this cancer is not yet understood. We
have demonstrated that gain of 12p is related to invasive growth and that
amplification of specific 12p sequences, i.e., 12p11.2-p12.1, correlates with
reduced apoptosis in the tumors. Here we show that three known genes
map within the newly determined shortest region of overlap of amplifi-
cation (SROA): DAD-R, SOX5, and EKI1. Whereas EKI1 maps close to the
telomeric region of the SROA, DAD-R is the first gene at the centromeric
region within the 12p amplicon. Although all three genes are amplified to
the same level within the SROA, expression of DAD-R is significantly
up-regulated in seminomas with the restricted 12p amplification com-
pared with seminomas without this amplicon. DAD-R is also highly ex-
pressed in nonseminomas of various histologies and derived cell lines, both
lacking such amplification. This finding is of particular interest because
seminomas with the restricted 12p amplification and nonseminomas are
manifested clinically in the third decade of life and show a low degree of
apoptosis. In contrast, seminomas lacking a restricted 12p amplification,
showing significantly lower levels of DAD-R with pronounced apoptosis,
manifest clinically in the fourth decade of life. A low level of DAD-R
expression is also observed in normal testicular parenchyma and in pa-
renchyma containing the precursor cells of this cancer, i.e., carcinoma in
situ. Therefore, elevated DAD-R expression in seminomas and nonsemi-
nomas correlates with invasive growth and a reduced level of apoptosis
associated with an earlier clinical presentation. These data implicate
DAD-R as a candidate gene responsible in part for the pathological effects
resulting from gain of 12p sequences in TGCTs. In addition, our results
also imply differences in expression regulation of DAD-R between semi-
nomas and nonseminomas.
INTRODUCTION
Invasive TGCTs,3 the most frequent cancers in Caucasian males
between the ages of 15 and 40 years (1), are clinically and histolog-
ically divided into seminomas and nonseminomas (2). Epidemiolog-
ical data supported by morphological and immunohistochemical stud-
ies indicate that the initial event in the pathogenesis of this cancer
occurs during fetal development, leading to CIS (3–7). Several studies
have provided insight into the progression of TGCTs. For example,
genomic analyses have revealed that polyploidization is an early and
crucial event, leading to invasive TGCTs with a total chromosomal
content in the triploid range (8, 9). In addition to aneuploidy, the most
consistent chromosomal anomaly found in invasive TGCTs is a rel-
ative gain of the short arm of chromosome 12, mediated by isochro-
mosome 12p [i(12p)] formation in up to 80% of cases (see Refs. 10,
11 for review). The remaining 20% of i(12p)-negative TGCTs also
contain additional copies of the short arm of chromosome 12 (12, 13).
This finding indicates that an increased copy number of one or more
genes located on 12p plays a role in the development of TGCTs.
Although a gain of 12p sequences in invasive TGCTs was reported in
1982 (14), the underlying molecular basis for this condition has not
yet been elucidated. We recently demonstrated that gain of 12p
sequences is not detectable in CIS (15), indicating that overrepresen-
tation of 12p is related to invasive growth of TGCTs. We further
found that tumor cells derived from seminomas with a restricted 12p
amplification, like nonseminomas, could be cultured for a few days in
vitro, whereas seminomas lacking this amplification could not be
grown in culture (16, 17). In fact, to date no cell lines of seminomas
are available (18). Furthermore, patients with seminomas that carry a
restricted 12p amplification are significantly younger at clinical pres-
entation than other seminoma patients (17). In fact, they have the
same age as patients with a nonseminoma.
These findings are consistent with the observation that seminomas
with a restricted 12p amplification show reduced apoptosis compared
with seminomas without such an amplification, whereas no differ-
ences in proliferation index are observed (17). We also showed that
the presence of a restricted 12p amplification is related to invasive
growth of the tumor cells in vivo. Overall, these data support a model
whereby overexpression or ectopic expression of one or more genes
on 12p permits survival of tumor cells in their invasive growth phase.
Previous studies indicated that three known genes are mapped within
the SROA on 12p in TGCTs: JAW1, KRAS2, and SOX5 (16, 17).
Although JAW1 was not considered a gene of interest, because ex-
pression is most likely explained by the presence of infiltrating
lymphocytes, no convincing data could be obtained supporting one of
the other genes as candidate.
Here we extend the study on the restricted 12p amplification as
found in TGCTs. We determined both the centromeric and telomeric
breakpoints in more detail and investigated the copy numbers and
expression levels of the genes mapped close to the breakpoints of the
SROA. Interestingly, a gene is located at both the telomeric and
centromeric side of the amplicon that is possibly involved in reduction
of apoptotic cell death. Specifically, a novel intronless gene, desig-
nated DAD-R, recently assigned to the short arm of chromosome 12,
band p11.2-p12.1 (19), maps the closest to the centromeric border of
the amplicon and shows up-regulation in TGCTs with a low level of
apoptosis. In fact, the newly determined breakpoint excludes JAW1
and KRAS2 from the SROA (16, 17). Although the precise function of
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DAD-R is not yet known, a highly homologous gene, DAD-1, plays a
role in apoptosis (20, 21) and is likely involved in N-glycosylation
(22–24). Inactivation of DAD-1 in mice results in induction of apo-
ptosis, suggesting that the wild-type gene has a protective function.
These mice show abnormal N-linked glycolipids (25). In addition, we
demonstrate that EKI1 maps to the telomeric region of the restricted
12p amplification in TGCTs. This gene encodes ethanolamine kinase,
which is the first committed step in phosphatidylethanolamine syn-
thesis via the CDP-ethanolamine pathway (26). Interestingly, ethanol-
amine kinase-overexpressing cells are protected against apoptotic cell
death (27). Our expression study shows that DAD-R, SOX5, and EKI1
are expressed at relatively low levels in testicular parenchyma sam-
ples and that the expression levels of DAD-R and EKI1 are independ-
ent of the presence of spermatogenesis or CIS. Although all three
genes show higher expression levels in invasive TGCTs, DAD-R
shows a specific and significant increased expression in seminomas
with the restricted 12p amplification and nonseminomas without this
amplification. The results also indicate that DAD-R is expressed
mainly in TGCTs with a low intrinsic sensitivity to apoptosis and is
therefore a candidate gene involved in the pathogenesis of TGCTs.
MATERIALS AND METHODS
Samples. Freshly obtained tumor samples included in this study were
collected in close collaboration with urologists and pathologists in the south-
western part of the Netherlands. All tumors were obtained before chemother-
apy and/or irradiation. Directly after surgical removal, representative parts of
the tumor and adjacent normal tissue (when available) were snap-frozen, and
other tissue samples were fixed overnight in 10% buffered formalin and
embedded in paraffin. The tumors were evaluated according to the WHO
classification for testicular tumors (2). Tumors containing both a seminoma
and a nonseminoma component were classified as combined tumors, according
to the British classification (28), instead of nonseminomas according to the
WHO classification system. Identification of CIS, seminoma, and embryonal
carcinoma was aided by direct enzyme-histochemical detection of alkaline
phosphatase activity on representative frozen tissue sections, as reported pre-
viously (29). Activated lymphocytes were prepared from in vitro phytohem-
agglutinin-stimulated peripheral blood lymphocytes cultures from three
healthy males with (46,XY) karyotype, as described previously (30). Non-
stimulated peripheral blood lymphocytes were harvested from a Ficoll gradient
directly after collection. The cell lines used, NTera2, 2102Ep, and NCCIT,
were cultured as reported previously (30, 31). RNA isolation and cDNA
synthesis were performed as described below.
FISH. For each case analyzed, 4-m-thick frozen tissue sections were cut
and air-dried at room temperature for 60 min on microscope slides treated with
3-aminopropyltriethoxysilane (Sigma Chemical Co., St. Louis, MO). In addi-
tion, two adjacent sections were used for histological examination. One was
stained with H&E and the other for alkaline phosphatase activity. Slides for
FISH were submerged in methanol-acetone (1:1, v/v) at 20°C for 20 min,
dehydrated in an increasing ethanol series (80, 90, and 100%; 2 min each), and
air-dried. Subsequently, tissue sections were treated with 0.0005% pepsin
(Sigma Chemical Co.) in 0.01 M HCl for 1 min at 37°C, washed five times for
1 min in water, and dehydrated. Hybridization was performed essentially as
described for the methanol-acetic acid fixed nuclei (16). All probes used were
labeled by nick translation. Probe 1A1, also known as 778I17 (mapping within
the SROA, containing SOX5; see Fig. 1A) was used as a control probe in all
experiments. Probe 1A1 was labeled with digoxigenin-11-dUTP (Roche,
Mannheim, Germany) and visualized with FITC-conjugated sheep antidigoxi-
genin (Roche). A restricted 12p amplification was defined as the presence of
15 signals/interphase nucleus, as described previously (16, 17).
Newly identified TGCTs with a restricted 12p amplification (see “Results”)
underwent a more detailed analysis to determine the position of breakpoints. In
these cases, the control probe was hybridized with several test probes (see Fig.
1A). Specifically, for the centromeric region probes containing KRAS2 (cosmid
clone), JAW1 (PAC 524I18), and DAD-R (BAC 622I13), as well as a 20-kb
centromeric end-clone derived from BAC 622I13 were used. For the telomeric
region BAC 49G2, cosmid C34F8, BACs 449P1 and 268P4 were used. The
latter two clones contain the EKI1 gene. In the initial experiments, the control
probe was labeled with digoxigenin-11-dUTP as described above, whereas test
probes were labeled with biotin-16-dUTP and detected using avidin-CY3
(Jackson ImmunoResearch Laboratories). To verify the results, the labels on
the probes were switched. The criteria used to determine the borders of the
breakpoints were similar to those described previously (16, 17). Briefly, the
test probe was scored as part of the amplicon when paired hybridization signals
with the control probe were observed, and scored as outside the amplicon when
the number of hybridization signals were found to be at least half compared
with the control probe.
Centromeric Clone Order Determination. A contiguous sequence of 277
kb containing the complete sequences of the genes JAW1 and DAD-R was
assembled from the National Center for Biotechnology Information database.4
This contig also contains the STSs D12S1617 and D12S1435. The sequence
was generated based on the completely sequenced clones 713N11 (AC023510)
and 662I13 (AC026310). The alignment was reconfirmed by medium- and
long-range DNA fingerprinting and Southern blot hybridization of BACs
713N11 (AC023510) and 662I13 (AC026310). The probes used for the map-
ping were derived both from the ends and from internal restriction fragments
of the aforementioned BAC clones. In addition, the order was confirmed using
fiber-FISH on normal DNA, as described previously (32).
Southern Blot Analysis of Breakpoints. High-molecular weight DNA
was isolated from a series of TGCTs with (six seminomas) and without (four
seminomas, three embryonal carcinomas, two yolk sac tumors, and three
teratomas) the restricted 12p amplification according to standard procedures
(33). Genomic DNA was digested separately with EcoRI and BglII and with a
combination of both. After electrophoresis through a 0.6% agarose gel, the
DNA was blotted onto Hybond N filters (Amersham). The filters were
hybridized with a PCR generated cDNA probe (see section on semiquantitative
RT-PCR below) labeled with [-32P]dATP. The expected sizes of the DNA
fragments obtained from the digests were 15.1 kb for EcoRI, 4.1 kb for BglII,
and 3.2 kb for the double digest.
Semiquantitative RT-PCR. RNA was isolated from snap-frozen tissue
samples with Trizol reagent (Life Technologies, Inc.) according to the manu-
facturer’s instructions. For reference, the histological composition of the
sample under investigation was checked by microscopic analysis of an adja-
cent section stained with H&E. The following samples were investigated:
lymphocytes (n 1); normal testicular parenchyma (n 5); atrophic testicular
parenchyma (n  1); testicular parenchyma with 20% CIS (n  2), 50% CIS
(n  2), or 80% CIS (n  2); seminoma without the restricted 12p amplifi-
cation (n  4); seminoma with the restricted 12p amplification (n  11);
embryonal carcinoma (n  3); teratoma (n  3); and yolk sac tumor (n  3).
All of these nonseminomas did not contain a restricted 12p amplification.
All RNA samples were pretreated with RNase-free DNase-I according to
standard method (34). The RNA pellets were dissolved in diethyl pyrocarbon-
ate-treated water. Complete removal of contaminating DNA is particularly
important in this case because DAD-R lacks introns (19). The resulting RNA
quality was checked by electrophoresis on a denaturing gel. To verify that the
RNA samples were free of DNA, 0.5 g of total RNA was used as template
in a PCR amplification with the primers DADR1a (5-AGTGTCAGGCAC-
CCGATGG-3) and DADR2a (5-GATGGTGCTAGCAAAGAGAAAG-3),
which generate a 293-bp fragment. These DAD-R primers differ from those
used by Kuittinen et al. (19). For expression analysis of SOX5 and EKI1, the
following primers were used: SOX5F (5-TGCCTGGTGGATGGCAAA-
AAGC-3) and SOX5R (5-GTTAATGTGCTTGGCCAC-3), which generate
a fragment of 477 bp (35), and EKI1F2 (5-TGGATCCAAAGCATGTCTG-
3) and EKI1R3 (5-TCATCTGCAAATCCTGTGGG-3), which generate a
fragment of 162 bp.
First-strand cDNA was synthesized from 1 g of oligo(dT) and random
hexamer primed DNase-I-treated RNA in a total volume of 40 l according to
standard procedures. The cDNA quality was checked by PCR with the primers
HPRT 243 and HPRT 244, which amplify a specific 387-bp fragment from
mRNA encoding the housekeeping gene HPRT (36).
For semiquantitative PCR, 0.5 l (12.5 ng of cDNA) of each reverse
transcription reaction was amplified with 0.2 M each of the test primers,
together with HPRT 243 and HPRT 244 in a volume of 50 l. In addition to
4 http://www.ncbi.nlm.nih.gov.
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0.125 mM dNTPs, each PCR reaction was supplemented with 0.25 l of
[-32P]dATP (10 Ci/l). After an initial denaturation step of 2 min at 94°C,
the cycling conditions used were as follows: 94°C for 30 s, 59°C for 30 s, and
72°C for 30 s. Ten-l aliquots were taken during the amplification, typically
after 17, 19, 21, and 23 cycles. Five l of loading buffer were added to each
aliquot, and 4 l were run on 4% native polyacrylamide gels. The gels were
scanned on a Storm-820 Phosphor Imager (Molecular Dynamics), and the band
intensities were quantified with the ImageQuant 5.0 Software.
We showed that the amplification products derived from DAD-R and not
from DAD-1 by digesting a 2-l aliquot from the last cycle of each sample
with PstI. This restriction endonuclease digests the amplification product of
DAD-R twice. In addition, we used AvaI, which has no recognition site in
DAD-R, in contrast to DAD-1 (D15057; National Center for Biotechnology
Information database). The expected digestion fragments of 186, 57, and 49 bp
were obtained from the PstI digestion, whereas the amplification products were
not digested by AvaI. Expression levels of DAD-R, SOX5, and EKI1 were
calculated as a ratio of HPRT. At least two consecutive data points that showed
linear amplification of the products of both genes were chosen for the calcu-
lation. The final data were obtained from the results of at least two independent
PCR reactions for each cDNA sample. The expression levels of KRAS2,
DAD-R, and HPRT were analyzed by a triple RT-PCR on RNA derived from
microdissected seminoma cells. The procedure was performed as described
above, except that 0.20 mM rather than 0.125 mM was used for dGTP, dCTP,
and dTTP, along with 0.15 mM dATP. The KRAS2-specific primers have been
described (16). For analysis, samples were taken after 20, 21, 22, 23, 24, and
25 amplification cycles.
Detection of Apoptosis Level. The level of apoptosis was determined by
electrophoresis of 1 g of high-molecular weight DNA isolated from snap-
frozen histologically checked TGCTs with and without a restricted 12p am-
plification, as described previously (17). The presence of DNA laddering was
visualized by ethidium bromide staining. Both seminomas with a restricted 12p
amplification as well as seminomas and nonseminomas without a restricted
12p amplification were included in this analysis.
Microdissection of Seminoma Cells. Twenty-m-thick tissue sections
from frozen samples were cut and stained for enzymatic alkaline phosphatase
activity as reported (15) and air dried. The cells of interest were microdissected
using the Arcturus Pixcell II system. Total RNA from the laser-captured
microdissected samples was isolated by adding 500 l of Trizol reagent and
incubating overnight at room temperature. RNA was DNase-I treated as
described above, and the RNA pellet was dissolved in 10 l of Tris-EDTA. For
the semiquantitative analysis, 2.5 l were used.
RESULTS
Presence of a Restricted 12p Amplification Correlates with a
Younger Age of Patients at Clinical Presentation. Our previous
studies had suggested that patients with seminomas containing a
restricted 12p amplification show clinical symptoms at a significantly
younger age than patients without this anomaly (17). Therefore, we
chose to analyze tissue samples from seminomas from patients diag-
nosed at an age younger than 30 years. These samples were screened
Fig. 1. A, schematic diagram of the centromeric and telomeric borders of the restricted 12p amplification found in invasive TGCTs in adolescents and adults. Genes, STSs, and probes
used are shown. Cosmids are C34F8, 102C10, 196E8, and KRAS2 (indicated by gray boxes), BACs and PACs are indicated by open boxes, and yeast artificial chromosomes by striped
boxes. The thick black line indicates the region included in the restricted 12p amplification determined in our previous studies. The present study identified tumors in which the SROA
is shorter, 2.2 Mb in length, indicated by the thick gray line. The STSs, probes, and genes are not presented to scale. B, physical map of the centromeric breakpoint region of the
SROA. The STSs, genes (including exons as black boxes), and probes are indicated to scale. Note the localization of the 22-kb end probe.
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by FISH with a probe (1A1  PAC 778I17, positive for SOX5) that
maps approximately in the middle of the SROA (see Fig. 1A). Of 45
cases analyzed, 8 tumors showed an amplicon, amounting to a 16%
incidence of seminomas with a restricted 12p amplification. This is a
2-fold increase compared with the general incidence in TGCTs, which
is 8% (16). To further investigate the relationship between the
presence of a restricted 12p amplification and the age of the patients
at clinical diagnosis, we tabulated the clinical data obtained from all
of the patients we have analyzed for the presence of a restricted 12p
amplification from our tumor bank according to age and histology of
the tumors. The results are shown in Fig. 2 and indicate that patients
with a 12p amplification-positive seminoma were significantly
younger (mean age, 29.7 years) than those without the amplification
(mean age, 36.0 years; P 0.01). In contrast, no age differences were
observed in patients with a nonseminoma or a combined tumor
(containing both a seminoma and a nonseminoma component) with
and without a restricted 12p amplification. Patients with a seminoma
containing a restricted 12p amplification were of the same age at
clinical diagnosis as patients with a nonseminoma.
Refinement of SROA and Localization of DAD-R. We have
previously shown that the centromeric and telomeric breakpoints
cluster to relatively small regions (17). To define more precisely the
breakpoints of the amplicon, we have analyzed a total of 21 semino-
mas and 5 nonseminomas with a restricted 12p amplification identi-
fied previously (Refs. 16, 17 and in this study). The copy numbers of
the amplicon, as identified by FISH with the 1A1 probe, varied
between 15 and 50 per nucleus on tissue sections. The majority of
tumors showed 20–35 copies/interphase nucleus on a tissue section.
The centromeric border of the amplicon was mapped with a series of
probes moving inward from KRAS2 toward the center of the amplicon.
A total of five probes were used (Fig. 1 and “Materials and Meth-
ods”). The results indicate that 9 of 21 seminomas (43%) and 1 of 5
nonseminomas (20%) with a restricted 12p amplification had at least
two times more copy numbers of the sequences that are part of BAC
662I13 and the cosmid probe for STS D12S1617 compared with the
control probe (see Fig. 3). The probability that this occurs by chance
in the group of seminomas is 1.29 1020 (see Ref. 17 for calcula-
tion). Analysis of the public databases showed that the region around
the centromeric breakpoint of the amplicon is gene poor, but more
interestingly, they indicate that DAD-R, a newly identified gene,
mapped only 20–25 kb from the breakpoint. Southern blot analysis
(using a cDNA PCR amplification product as probe) of seminomas
with and without a restricted 12p amplification and a series of non-
seminomas without the amplification showed the absence of any
aberrant genomic bands, indicating the absence of rearrangements
within a 16–20-kb region near the DAD-R coding sequence (data not
shown).
At the telomeric side of the amplicon a similar approach was
performed. Here, four different probes in combination with the control
probe (1A1) were used (see Fig. 1A). Whereas four seminomas
showed at least half the number of signals when C34F8 was used as
probe compared with the control probe, this was the case for only one
when 49G2 was used as probe. These results were confirmed with the
other two probes (449P1 and 268P4) as well as with the same probes,
but labeled conversely. In total, 4 of the 21 seminomas (19%) showed
the telomeric breakpoint between C34F8 and 449P1/268P4. The prob-
ability for this phenomenon by chance is 7.2 106. These results
indicate that the breakpoints at the telomeric side of the amplicon are
less, although still highly significantly clustered than those at the
centromeric side (see above). In fact, one of the tumors had the SROA
as the actual amplicon. The first known gene present within the SROA
at the telomeric side was found to be EKI1. Therefore, in the semi-
noma with the smallest amplified fragment, EKI1 and DAD-R are
located at the borders of the amplified region.
Fig. 2. Scatter plot of the ages at clinical presentation of patients with a nonseminoma
without (NS) and with (NS) a restricted 12p amplification, seminoma without (SE)
and with (SE) a restricted 12p amplification, or a combined tumor without (CT) and
with (CT) a restricted 12p amplification. Note the significant age difference between
SE and SE, the latter being similar to NS ( and ). Indicated are the ages at clinical
presentation, mean and SE (bars). See text for statistics.
Fig. 3. A, representative example of FISH anal-
ysis of a frozen tissue section of a seminoma with
a restricted 12p amplification, using the control
probe (1A1, in red) and a probe positive for KRAS2
(in green), indicating a lower copy number of the
latter compared with the former. B, representative
example of FISH analysis of the same tumor shown
in A, using the control probe (1A1, in red) and the
centromeric end probe BAC 662I13 (in green; see
also Fig. 1), indicating a lower number of hybrid-
ization signals of the latter compared with the
former.
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Expression Analysis of DAD-R, SOX5, and EKI1. Because of the
significant clustering of breakpoints at both the centromeric and
telomeric borders of the restricted 12p amplification, the expression
levels of the two genes mapped close to the borders, as well as SOX5,
were analyzed in TGCTs with various histological compositions and
gene copy numbers and a series of control samples by semiquantita-
tive RT-PCR. The results of expression analysis are summarized in
Fig. 4A, and representative examples for DAD-R are shown in Fig. 4B.
The control samples showed a low level of expression of DAD-R,
SOX5, and EKI1. Transcripts were detected in activated lymphocytes
only after 28 PCR amplification cycles. Because the detection level
was below the linear range used to quantify the other samples, we
concluded that the contribution of RNA from these genes to the RNA
from lymphocytes in the samples under investigation is minimal. A
relatively low but quantifiable level of expression was detected in
testicular parenchyma with spermatogenesis. The expression levels of
DAD-R and EKI1 were similar to those detected in an atrophic
testicular parenchyma sample. In contrast, no expression of SOX5 was
observed in atrophic testis, which is expected because this gene is
specifically expressed during spermatogenesis (35). No significant
differences in the expression levels of these genes were found in
testicular parenchyma samples with various amounts of CIS. In con-
trast, all invasive TGCTs showed significantly higher expression
levels for all three genes within the SROA compared with the differ-
ent testicular parenchyma samples (P  0.001). However, only
DAD-R showed a significant difference in expression level between
the different histological groups of TGCTs. Seminomas without a
restricted 12p amplification showed the lowest expression level,
whereas a significantly higher level of expression was found in
seminomas with a restricted 12p amplification (P  0.0077). Only
one seminoma did not show enhanced expression (ratio, 0.16). Inter-
estingly, this case was found to be more similar to seminomas without
a restricted 12p amplification, as determined by cDNA array analy-
sis.5 One case showing intermediate expression (ratio, 0.37) was
found to contain a significant component of testicular parenchyma in
5 Unpublished results.
Fig. 4. A, summary of the expression analysis of DAD-R
(open columns), SOX5 (hatched columns), EKI1 (dark gray
columns), and KRAS2 (black columns) by semiquantitative RT-
PCR. The samples studied are activated lymphocytes (Lymph.),
normal testicular parenchyma (Paren.), atrophic testicular pa-
renchyma (Atroph.), testicular parenchyma with various
amounts of CIS (CIS) containing seminiferous tubules (20, 50,
and 80%), seminomas without a restricted 12p amplification
(SE), seminoma with a restricted 12p amplification (SE),
and nonseminomas of various histologies (EC, embryonal car-
cinoma; TE, teratoma; YS, yolk sac tumor). Indicated are the
ratios of expression of the target gene versus HPRT, mean and
SD (bars). B, representative examples of DAD-R expression of
the various groups tested (see legend for A for abbreviations
used, except YST, yolk sac tumor).
1826
DAD-R AND TESTICULAR GERM CELL TUMORS
the sample used for analysis. In one case, both the seminoma com-
ponent with the restricted 12p amplification and its adjacent paren-
chyma (with 80% CIS-containing seminiferous tubules) were in-
vestigated separately. In this specimen, high DAD-R expression was
detected only in the invasive component. These data support the
hypothesis that up-regulation of DAD-R expression is related to in-
vasive growth in TGCTs. Furthermore, none of the nonseminomas
tested (three embryonal carcinomas, two teratomas, and three yolk sac
tumors) contained a restricted 12p amplification, but all showed
higher DAD-R expression compared with testicular parenchyma and
seminomas without a restricted 12p amplification. In fact, the level of
expression was similar to that found in seminomas with the restricted
12p amplification. The lower DAD-R expression level in teratomas
was likely attributable to the low number of tumor cells in the samples
as judged from histology.
DAD-R and Apoptosis. We demonstrated previously that semino-
mas with a restricted 12p amplification showed a reduced level of
apoptosis compared with seminomas without a restricted 12p ampli-
fication (17). Here we confirm this finding by investigating a total of
15 seminomas [9 reported previously by this group (17)] with a
restricted 12p amplification, and we correlate this with DAD-R ex-
pression. Twelve of these tumors (80%) showed a low level of
apoptosis, detected by the presence of DNA laddering upon gel
electrophoresis. Eight of these were studied for the level of DAD-R
expression and showed a high expression, with the exception of one
(ratio, 0.37). This latter case contained a significant amount of testic-
ular parenchyma (see above). The two cases with a profound level of
apoptosis studied for DAD-R showed a low level of DAD-R expres-
sion (ratios, 0.16 and 0.46). In other words, all seminomas with a
restricted 12p amplification that had a DAD-R expression ratio 0.76
(n 7) also showed a low level of apoptosis. This correlation between
level of DAD-R expression and apoptosis was further supported by the
profound level of apoptosis in seminomas without a restricted 12p
amplification and with a low level of DAD-R expression (n  4;
average ratio, 0.20; SD, 0.02) and the low level of apoptosis in case
of high DAD-R expression in nonseminomas (n  9), of which
representative examples are shown in Fig. 5, as well as the findings in
the nonseminomatous cell lines (see below).
Expression Levels of KRAS2 versus DAD-R. To study the rela-
tionship between expression levels of DAD-R and KRAS2, which was
included in the amplified fragment in the majority of the TGCTs (see
above), triple semiquantitative RT-PCR including KRAS2, DAD-R,
and HPRT was performed. RNA was isolated from seminoma cells
microdissected from frozen tissue sections and stained enzymatically
for alkaline phosphatase to identify tumor cells (see Fig. 6A). This is
because activated lymphocytes also show expression of KRAS2 (data
not shown). Both seminomas without (n  3) and with (n  5) a
restricted 12p amplification were investigated, as demonstrated by
FISH with the control probe on an adjacent section (not shown). All
of the seminomas with a restricted 12p amplification showed in-
creased DAD-R expression (see above), which confirms the above-
mentioned results, which are based on nonmicrodissected material.
The results of the expression analyses are summarized in Fig. 6B, and
representative examples are shown in Fig. 6C. Note that no differ-
ences in KRAS2 expression were observed between seminomas with
and without a restricted 12p amplification (mean ratio of DAD-R to
HPRT, 0.23 and 0.28, respectively). In contrast, the DAD-R expres-
sion level was enhanced in the presence of an amplification. These
data demonstrate that the expression level of KRAS2 is not influenced
by the presence of a restricted 12p amplification, like SOX5 and EKI1,
indicating that alterations in expression levels of these genes cannot
account for the biological differences observed between seminomas
with and without a restricted 12p amplification.
Expression Analysis of DAD-R, SOX5, and EKI1 in TGCT-
derived Cell Lines. To further investigate the expression of these
genes in nonseminomas, we studied a series of representative cell
lines derived from nonseminomas. The copy numbers of the genes to
be investigated were determined by FISH and the expression levels by
semiquantitative RT-PCR. The results of the copy number analyses
are summarized in Table 1 and are in accordance to our previous
findings (30). The NTera2 cell line has two normal chromosomes 12
and two isochromosomes 12p. There are four normal chromosomes 12
and one isochromosome 12p in 2102Ep. The cell line NCCIT has
three to four normal chromosomes 12 and one derivative. The expres-
sion levels of the three genes mapped within the SROA are also
shown in Table 1 and indicate that expression of DAD-R is the
highest, being at a level similar to that of HPRT. No changes in
expression levels were observed by induction of differentiation by
retinoic acid. This supports the finding that the lower expression of
these genes detected in the clinical samples composed of teratomas
(see above) is attributable to the smaller amount of tumor cells present
in the samples analyzed.
DISCUSSION
Identification of potentially relevant genes that map to the short arm
of chromosome 12 is a major goal in the study of the pathogenesis of
TGCTs. Because of the consistent observation of additional copies of
12p in invasive TGCTs, it is likely that extra copies of genes on 12p
are a requirement for the tumor to become clinically overt. We have
proposed that in the progression from CIS to invasive tumor, genes on
12p prevent induction of apoptosis of tumor cells when they leave the
seminiferous tubules. This hypothesis was derived from analysis of
TGCTs with a restricted 12p amplification (16, 17). This region of
amplification is tandemly organized on one chromosome, and it is not
distributed throughout the genome (17, 37), which was shown both by
spectral karyotyping as well as by FISH using region-specific probes.
In addition, this has recently been supported by our finding that CIS
lacks a gain of 12p sequences (15). The study presented here is in
agreement with this model and identifies a putative candidate gene. In
a series of TGCTs with a restricted 12p amplification, we found that
the breakpoints of the amplicons clustered significantly to relatively
narrow regions at both the telomeric and centromeric ends (17). This
observation, confirmed in this study, suggests the presence of relevant
genes in those particular areas on which we focused in this study. Our
Fig. 5. Representative examples of the level of apoptosis as demonstrated by the
presence of DNA laddering after gel electrophoresis of 1 g of DNA and ethidium
bromide staining in seminomas without a restricted 12p amplification (left-hand lanes),
with a restricted 12p amplification (middle lanes), and nonseminomas (right-hand lanes).
The expression ratios for DAD-R (ratio versus HPRT) are indicated. M, marker.
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previous investigations revealed that three known genes map to the
SROA: (from centromeric to telomeric) KRAS2, JAW1, and SOX5 (16,
17), of which KRAS2 has been suggested to be the most likely
candidate (38). The mapping data presented in this report have ex-
cluded both KRAS2 and JAW1 from the SROA, thereby making them
less likely candidates. These data are in accordance to our KRAS2
expression analysis, which shows that the presence of a restricted 12p
amplification does not affect the expression level of this gene, indi-
cating that differences in KRAS2 expression cannot explain the bio-
logical differences between seminomas with and without a restricted
12p amplification. In addition, the putative role of KRAS2 in malig-
nant transformation has been questioned because of the discrepancy in
expression levels needed in in vitro and in vivo systems (39).
Two additional candidates mapping close to the borders of the
SROA have been identified in this study. We demonstrate that DAD-R
maps close to the centromeric border of the SROA. This gene is
highly homologous to DAD-1, which suppresses induction of apo-
ptosis (21, 22). In addition, EKI1 maps to the telomeric border of the
SROA, and overexpression of this gene has also been found to
suppress apoptotic cell death (40). Because of their localization and
possible functions, we investigated the copy numbers of these genes
within the restricted 12p amplification and determined their level of
Table 1 Results of the semiquantitative expression analysis (ratio to HPRT) of EKI1,






RAb 0.42 (7) 0.75 (7) 1.15 (7)
RA 0.40 (7) 0.80 (7) 1.10 (7)
2102EP
RA 0.38 (6) 0.65 (6) 1.10 (6)
 RA 0.39 (6) 0.70 (6) 1.05 (6)
NCCIT 0.41 (4–6) 0.60 (4) 1.15 (4)
a Gene copy number in parentheses.
b RA, retinoic acid.
Fig. 6. A, representative examples of a frozen histological sec-
tion of a seminoma before (left panel) and after (right panel)
microdissection of tumor cells by laser capture. Tumor cells are
specifically identified based on their enzymatic reactivity for alka-
line phosphatase. Note the purification of tumor cells. B, scatter plot
of results of semiquantitative expression analysis of KRAS2,
DAD-R, and HPRT within a single experiment (ratio for KRAS2/
HPRT, DAD-R/HPRT, and DAD-R/KRAS2) on seminomas without
(SE) and with (SE) a restricted 12p amplification. Note specific
up-regulation of DAD-R in case of seminomas with a restricted 12p
amplification, whereas no difference in KRAS2 expression is ob-
served. Indicated are the different ratios, mean and SE (bars). C,
two representative examples of the semiquantitative expression
analysis of KRAS2, DAD-R, and HPRT within a single experiment
on a seminoma without (SE) and with (SE) a restricted 12p
amplification.
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expression in the various histological variants of TGCTs and control
samples. No enhanced expression of these genes occurs in CIS-
containing parenchyma compared with normal and atrophic testicular
parenchyma. In contrast, all invasive TGCTs show significantly
higher levels of DAD-R mRNA and, to a lesser extent, of EKI1 and
SOX5. This indicates that the levels of expression of these genes are
related to invasive growth of this cancer, in accordance to our previ-
ous finding that gain of 12p is restricted to invasive TGCTs (15).
Although overexpression of EKI1 might prevent apoptotic cell death
(27), it seems not to be the most important gene within the SROA,
because no significant increase in expression related to copy numbers
of the gene was observed. Most striking is the finding that seminomas
with a restricted 12p amplification show specifically and significantly
higher expression levels of DAD-R (not of SOX5, EKI1, or KRAS2)
compared with seminomas without this amplification. This is despite
the similar copy numbers of the three genes within the SROA. The
difference in expression level of DAD-R between seminomas without
and with a restricted 12p amplification, 0.2 and 1.4 times the level
of HPRT (7-fold increase), is expected based on the copy numbers
per nucleus found. Seminomas without a restricted 12p amplification
contain in general 5–6 copy numbers of 12p per cell (10), whereas
seminomas with a restricted 12p amplification show 15–50 copy
numbers/nucleus on 4-m-thick tissue sections (see “Materials and
Methods”).
Interestingly, a expression level of DAD-R similar to that found in
the seminomas with the restricted 12p amplification was detected in
nonseminomas and derived cell lines, which lack a restricted 12p
amplification. On average, nonseminomas, and the derived cell lines
have six to seven copies of 12p per nucleus (10, 30).
The specific clustering of breakpoints at the centromeric side of
the amplicon, in contrast to a more heterogeneous, but still signif-
icant, pattern at the telomeric side, supports the importance of
DAD-R in the pathogenesis of TGCTs. Noteworthy in this context
is the finding that patients with a seminoma containing a restricted
12p amplification present at a age similar to that of patients with
a nonseminoma (Ref. 17 and this study). Moreover, seminomas
with a restricted 12p amplification as well as nonseminomas can be
grown in vitro for an extended period of time, and both are more
resistant to apoptosis (Refs. 17, 41 and this study). Neither of these
conditions were found for seminomas without a restricted 12p
amplification, which present at an older age. However, no differ-
ences in stage of the disease and treatment sensitivity of the cancer
that depend on the presence of a restricted 12p amplification have
been found (17). These results indicate that the level of DAD-R
expression is related to the likelihood of apoptosis, thereby influ-
encing the age of clinical manifestation of the tumor and, probably
by the same mechanism, the ability of the tumor cells to survive in
vitro. This model is schematically shown in Fig. 7. Our data also
indicate the existence of a different regulatory mechanism that
controls expression of DAD-R in seminomas than in nonsemino-
mas of various histologies, the latter being independent of copy
number. DAD-R expression does not seem to be influenced by
differentiation status, as confirmed with the cell lines tested before
and after differentiation induction by retinoic acid.
Fig. 7. Schematic representation of the model describing the role of gain and amplification of 12p in the development of TGCTs in adolescents and adults. The initiating
event occurs during prenatal development. This event affects an embryonic germ cell (likely a primordial germ cell), leading to CIS, which is localized to the inner side of
the basal membrane of seminiferous tubules under the tight junctions between Sertoli cells. CIS lacks gain and restricted amplification of 12p sequences. In contrast, all invasive
TGCTs, both seminomas and nonseminomas, have extra copies of 12p, either by gain or a restricted amplification, which allow invasive growth. Whereas seminomas normally
manifest themselves in the fourth decade of life, nonseminomas occur in the third decade of life. The higher level of apoptosis of seminomas compared with nonseminomas
might explain this age difference. The level of apoptosis inversely correlates with the expression levels of DAD-R, being low in seminomas and high in nonseminomas.
Seminomas with a restricted 12p amplification present clinically within the third decade of life and, like nonseminomas, show a low level of apoptosis and high expression
level of DAD-R. Our data implicate DAD-R as the most likely candidate gene to mediate the role of amplification of 12p in invasive TGCTs. Increased expression of DAD-R
results in a more profound inhibition of induction of apoptosis, allowing better survival of the tumor cells outside the specific microenvironment of the seminiferous tubules.
The expression level of DAD-R in nonseminomas is less dependent on the copy number of the gene, which may explain the higher incidence of restricted 12p amplification
in seminomas compared with nonseminomas.
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To date, this is the first report that links the level of expression of
DAD-R with a biological phenomenon. However, no direct proof is as
yet available that this gene encodes a functional protein. To better
elucidate the function of this gene, we are assessing the function of
DAD-R in model systems and determining the subcellular localization
of its protein product immunologically.6 Furthermore, we have pre-
liminary data that show that the coding sequences of DAD-R are
evolutionary conserved.7
In conclusion, we have demonstrated that the restricted 12p ampli-
fication as present in a selected series of TGCTs contains at least three
genes, DAD-R, SOX5, and EKI1. DAD-1 maps the closest to the
centromeric border of the SROA, and EKI1 to the telomeric border.
The highest clustering of breakpoints was found at the centromeric
breakpoint, close to DAD-R. Despite similar copy numbers within the
restricted 12p amplification, the expression of DAD-R is specifically
up-regulated, being associated with a reduced level of apoptosis. It
remains to be elucidated whether overexpression of DAD-R might
influence the pattern of N-glycosylation, as found for DAD-1 (25). We
demonstrated that seminomas indeed have a pattern of glycoproteins
different from that of nonseminomas (42), which might be related to
this phenomenon. These findings, together with our earlier results,
point to DAD-R as a likely candidate gene able to explain the advan-
tage of accumulating extra copies of 12p in the establishment of
invasive TGCTs.
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